AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Starpharma Holdings Limited (ASX:SPL) announced that they have successfully launched VivaGel® BV (an Australian innovation) in Australia through Aspen Pharmacare (Aspen) as Fleurstat BVgel. This is the first launch and distribution of product across Australia, following which further launches by Mundipharma are expected in Europe in May/June this year.
The product is a non-antibiotic therapy for the treatment of bacterial vaginosis (BV) and relief of symptoms, where bacterial vaginosis is the most common vaginal condition (twice as common as thrush). Bacterial vaginosis often has significant social impacts on women as it causes unpleasant vaginal odour and discharge symptoms. It has been associated with other serious reproductive health-related medical problems.
Fleurstat BVgel is being marketed in Australia by Aspen as a non-antibiotic therapy and only treatment for bacterial vaginosis available over-the-counter (OTC) at pharmacies, without the need for a prescription.
Starpharmaâs Chief Executive Officer, Dr. Jackie Fairley, stated that they are excited to achieve the important milestone of the first launch of VivaGel® BV in the world, in collaboration with their Australian partner, Aspen. The product is marketed as Fleurstat BVgel and is a real success story of an Australian innovation, which is rare to have a global healthcare product developed by an Australian company all the way from concept to commercialisation.
Head of Nutritionals & Consumer OTC (Over-the-Counter), Aspen Australia, Rob Barnes stated that they are excited to be the first company in the world to launch and make Fleurstat BVgel available to Australian women who would be able to purchase a BV product over-the-counter in pharmacies.
In a previous update, Starpharma Holdings announced its meeting with US FDA to clarify all the details related to the approval of VivaGel® BV in the US. The meeting was attended by senior officials of the company along with key leaders in BV and FDA regulatory consultants.
In another announcement, the company presented its operational highlights at Goldman Sachs Emerging Leaders Conference. The group noted that it comprises a deep portfolio of high-value global products with the potential to significantly improve patient outcomes, mainly VivaGel® portfolio and DEP® Drug delivery portfolio. Under VivaGel®, it has VivaGel® BV, VivaGel®condom, and SPL7013 ophthalmic. Under Internal DEP®, it has DEP® docetaxel, DEP® cabazitaxel, DEP® irinotecan, other targeted DEP®. Under partnered DEP®, it has AZ DEP® AZD0466, AZ #2 DEP® candidate, AZ #3 DEP® candidate, Antibody Drug Conjugate (ADC) #1 and #2.
On the stock information front, at the time of writing (on April 16, 2019, AEST: 02:00 PM) the stock of Starpharma Holdings was trading at $1.165, up 7.87% with a market capitalisation of ~$401.43 million. Today, it touched a dayâs high at $1.177 and dayâs low at $1.085, with a daily volume of more than 598,984. Its 52 weeks high stands at $1.662 and 52 weeks low at $0.87, with an average volume of 282,820. Its absolute return for five years, one year, six months, and three months are 44.16%, -1.77%, -25.25%, and 0.91%, respectively.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
